Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/IGLC2_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/IGLC2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IGLC2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IGLC2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/IGLC2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/IGLC2_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IGLC2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IGLC2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IGLC2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069112 | Cervix | HSIL_HPV | phagocytosis, engulfment | 14/737 | 127/18723 | 4.81e-04 | 7.00e-03 | 14 |
GO:00990242 | Cervix | HSIL_HPV | plasma membrane invagination | 14/737 | 136/18723 | 9.54e-04 | 1.19e-02 | 14 |
GO:0050871 | Cervix | HSIL_HPV | positive regulation of B cell activation | 14/737 | 152/18723 | 2.75e-03 | 2.61e-02 | 14 |
GO:0042113 | Cervix | HSIL_HPV | B cell activation | 24/737 | 334/18723 | 3.48e-03 | 3.14e-02 | 24 |
GO:00024432 | Cervix | N_HPV | leukocyte mediated immunity | 39/534 | 440/18723 | 3.94e-10 | 2.24e-07 | 39 |
GO:000695921 | Cervix | N_HPV | humoral immune response | 31/534 | 317/18723 | 2.53e-09 | 7.88e-07 | 31 |
GO:000246021 | Cervix | N_HPV | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 33/534 | 356/18723 | 2.99e-09 | 8.02e-07 | 33 |
GO:000244911 | Cervix | N_HPV | lymphocyte mediated immunity | 32/534 | 350/18723 | 7.29e-09 | 1.58e-06 | 32 |
GO:000269621 | Cervix | N_HPV | positive regulation of leukocyte activation | 34/534 | 409/18723 | 2.69e-08 | 3.40e-06 | 34 |
GO:005086721 | Cervix | N_HPV | positive regulation of cell activation | 34/534 | 420/18723 | 5.14e-08 | 5.59e-06 | 34 |
GO:000276421 | Cervix | N_HPV | immune response-regulating signaling pathway | 36/534 | 468/18723 | 7.52e-08 | 7.81e-06 | 36 |
GO:004274211 | Cervix | N_HPV | defense response to bacterium | 28/534 | 350/18723 | 9.96e-07 | 5.53e-05 | 28 |
GO:005125121 | Cervix | N_HPV | positive regulation of lymphocyte activation | 28/534 | 362/18723 | 1.93e-06 | 9.68e-05 | 28 |
GO:001606411 | Cervix | N_HPV | immunoglobulin mediated immune response | 20/534 | 207/18723 | 2.10e-06 | 1.01e-04 | 20 |
GO:001972411 | Cervix | N_HPV | B cell mediated immunity | 20/534 | 210/18723 | 2.63e-06 | 1.17e-04 | 20 |
GO:001032421 | Cervix | N_HPV | membrane invagination | 15/534 | 144/18723 | 1.60e-05 | 4.86e-04 | 15 |
GO:00069111 | Cervix | N_HPV | phagocytosis, engulfment | 14/534 | 127/18723 | 1.61e-05 | 4.86e-04 | 14 |
GO:000225321 | Cervix | N_HPV | activation of immune response | 26/534 | 375/18723 | 3.06e-05 | 8.02e-04 | 26 |
GO:00990241 | Cervix | N_HPV | plasma membrane invagination | 14/534 | 136/18723 | 3.49e-05 | 8.79e-04 | 14 |
GO:000695611 | Cervix | N_HPV | complement activation | 13/534 | 130/18723 | 8.91e-05 | 1.86e-03 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGLC2 | SNV | Missense_Mutation | novel | c.22N>T | p.Ser8Leu | p.S8L | | IG_C_gene | deleterious_low_confidence(0) | benign(0.023) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
IGLC2 | SNV | Missense_Mutation | rs371508809 | c.151N>T | p.Ala51Val | p.A51V | | IG_C_gene | deleterious_low_confidence(0) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.130N>A | p.Ala44Glu | p.A44E | | IG_C_gene | deleterious_low_confidence(0) | benign(0.272) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
IGLC2 | SNV | Missense_Mutation | rs759610154 | c.280N>T | p.Ser94Ile | p.S94I | | IG_C_gene | deleterious_low_confidence(0) | benign(0.067) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.12N>A | p.Ala5Thr | p.A5T | | IG_C_gene | deleterious_low_confidence(0) | benign(0.027) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IGLC2 | SNV | Missense_Mutation | novel | c.226N>T | p.Pro76Leu | p.P76L | | IG_C_gene | deleterious_low_confidence(0) | possibly_damaging(0.494) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.177N>G | p.Lys60Glu | p.K60E | | IG_C_gene | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | rs755014029 | c.223N>T | p.Thr75Met | p.T75M | | IG_C_gene | deleterious_low_confidence(0) | benign(0.349) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.22C>T | p.Ser8Leu | p.S8L | | IG_C_gene | deleterious_low_confidence(0) | benign(0.023) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.136N>A | p.Ser46Asn | p.S46N | | IG_C_gene | deleterious_low_confidence(0) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |